Your Meds Aren't Working Right. Your Genes May Explain Why.

CYP2D6 is one of your liver’s workhorse enzymes. It does the metabolic heavy lifting for antidepressants like sertraline and paroxetine, opioid painkillers like codeine and tramadol, beta-blockers used for heart rate control, and dozens of other common medications. If CYP2D6 is working normally, it breaks these drugs down efficiently and your body can eliminate them.

But if you carry certain variants in the CYP2D6 gene, your enzyme works much more slowly. Roughly 7-10% of people with European ancestry are poor metabolizers of CYP2D6 substrates. When you’re a poor metabolizer, drugs accumulate in your system because your liver can’t break them down fast enough. A standard dose becomes a toxic dose. You develop side effects that feel like the medication is poisoning you, even though you’re taking exactly what your doctor prescribed.

You might experience extreme fatigue from an antidepressant, severe constipation or respiratory depression from an opioid, or a dangerously slow heart rate from a beta-blocker. You tell your doctor the medication made you feel worse. The medication gets blamed. But the real problem is that your genes process it too slowly.

CYP2C19 metabolizes clopidogrel (Plavix), a blood thinner prescribed after heart attacks and stent placement. It also breaks down proton pump inhibitors like omeprazole (used for acid reflux), and several antidepressants. This enzyme is particularly important because clopidogrel is a prodrug, meaning your liver must activate it for it to work.

If you carry CYP2C19 poor metabolizer variants, your liver cannot activate clopidogrel properly. Roughly 2-15% of people carry these variants, depending on ancestry. Poor metabolizers get almost no antiplatelet benefit from clopidogrel, leaving them vulnerable to blood clots after stent placement. This is not a minor effect. Studies show poor metabolizers have significantly higher rates of stent thrombosis (clots forming inside the stent).

You may feel fine after a stent placement because you’re taking your blood thinner as directed. But at the genetic level, your blood is just as prone to clotting as if you weren’t taking it at all. The protection your cardiologist prescribed isn’t there.

CYP2C9 breaks down warfarin, the oral anticoagulant prescribed for atrial fibrillation and clotting disorders. It also metabolizes NSAIDs like ibuprofen and naproxen, and several statins. Warfarin has a narrow therapeutic window, meaning the difference between an effective dose and a bleeding dose is small.

If you carry CYP2C9 poor metabolizer variants (roughly 5-10% of people with European ancestry), your liver clears warfarin much more slowly. Standard warfarin doses can accumulate to dangerous levels in your blood, causing spontaneous bleeding from your gums, nose, or GI tract. Meanwhile, your INR (international normalized ratio, the measure of blood clotting) climbs into the danger zone.

You might start on a standard warfarin dose and within days develop bruising that seems out of proportion to any injury. You bleed from minor cuts. Your gums bleed when you brush your teeth. If nobody knows you’re a poor metabolizer, these bleeds can go unnoticed until they become serious.

VKORC1 encodes vitamin K epoxide reductase, the enzyme that warfarin targets. VKORC1 is not a metabolizer gene, it’s a target gene. Your warfarin works by blocking VKORC1, which prevents vitamin K recycling in your cells. This disrupts the clotting cascade and thins your blood.

If you carry the A allele variant in VKORC1 (present in roughly 40% of people with European ancestry), your VKORC1 enzyme is inherently less active. Your blood is already partially resistant to vitamin K recycling, so warfarin has an outsized effect on your system. You need much lower doses than average to achieve therapeutic anticoagulation.

You might start on a standard warfarin dose and find your INR shoots above the therapeutic range, requiring dose reductions. You bleed more easily on lower doses than people without the variant would on higher doses. Your anticoagulation feels unstable and requires more frequent monitoring.

SLCO1B1 encodes a transporter protein that pulls statins from your bloodstream into your liver cells, where they do their job of lowering cholesterol. This is a transporter gene, not a metabolizer gene, but it’s just as critical. If your transporter doesn’t work well, statins accumulate in your blood instead of concentrating in your liver.

If you carry the SLCO1B1 variant (the C allele, present in roughly 15% of the population), your statin transporter is impaired. Statins build up in your bloodstream and muscle tissue, significantly increasing your risk of statin-induced myopathy, the breakdown of muscle fiber. You start taking a statin for cholesterol and weeks later develop unexplained muscle pain, weakness, or dark urine (a sign of muscle breakdown).

You might attribute the muscle pain to exercise or aging. Your doctor might assume you’re pushing too hard at the gym. If the statin doesn’t get stopped, the muscle breakdown can progress to rhabdomyolysis, a life-threatening condition. You feel fine on the dose your cardiologist prescribed. Your cholesterol drops beautifully. But your muscles are being quietly damaged.

TPMT breaks down thiopurine drugs like azathioprine and 6-mercaptopurine, immunosuppressants used for autoimmune diseases, transplant rejection prevention, and certain cancers. These drugs are powerful and toxic if levels get too high. TPMT is the primary safeguard.

If you’re a poor metabolizer of TPMT (roughly 0.3% of the population), your liver cannot break down thiopurines efficiently. These toxic metabolites accumulate in your cells, particularly in bone marrow cells, causing severe bone marrow suppression. You develop dangerous drops in white blood cells, red blood cells, and platelets. Your immune system becomes unable to fight infection. You develop anemia. You bruise and bleed easily.

You start an immunosuppressant at a standard dose for your condition. Within weeks you develop severe fatigue, repeated infections, or spontaneous bruising. You go to the ER with a dangerously low white blood cell count. TPMT testing after the fact reveals you should have been on a fraction of the dose all along.